Intra-articular Fibroma of Tendon Sheath in Knee Joint Associated with Iliotibial Band Friction Syndrome: Rare Occurrence in a Teenage Girl.

INTRODUCTION: Iliotibial band (ITB) friction syndrome is a common overuse injury typically seen in active athlete population. A nodular lesion on the inner side of the ITB as an etiology or an accompanying lesion with friction syndrome has rarely been reported. Among such nodular lesions around knee, fibroma of tendon sheath (FTS) is a rare occurrence. All the more intra-articular occurrence is extremely rare. CASE REPORT: A 16-year-old female presented with recurrent pain and movable nodule at the lateral joint area, diagnosed as ITB friction syndrome. The nodule was confirmed as rare intra-articular FTS on the basis of histopathology findings. CONCLUSION: When nodular lesions around knee are detected on magnetic resonance imaging, a FTS could be included in the differential diagnosis. Etiology and pathogenesis of ITB friction syndrome should be revised in view of such rare presentations.

Spontaneous and stimulated emission spectroscopy of a Nd(3+)-doped phosphate glass under wavelength selective pumping.

The influence of the host matrix on the spectroscopic and laser properties of Nd(3+) in a K-Ba-Al phosphate glass has been investigated as a function of rare-earth concentration. Site-selective time resolved laser spectroscopy and stimulated emission experiments under selective wavelength laser pumping show the existence of a very complex crystal field site distribution of Nd(3+) ions in this glass. The peak of the broad stimulated (4)F(3/2)→(4)I(11/2) emission shifts in a non monotonous way up to 3 nm as a function of the excitation wavelength. This behavior can be explained by the relatively moderate inter-site energy transfer among Nd(3+) ions found in this system and measured by using fluorescence line narrowing spectroscopy. The best slope efficiency obtained for the laser emission was 40%.

Anaerobic treatment and biogas recovery for sago wastewater management using a fluidized bed reactor.

Starch manufacturing industrial units, such as sago mills, both at medium and large scale, suffer from inadequate treatment and disposal problems due to high concentration of suspended solid content present in the effluent. In order to investigate the viability of treatment of sago effluent, a laboratory scale study was conducted. The treatment of sago effluent was studied in a continuous flow anaerobic fluidized bed reactor. The start-up of the reactor was carried out using a mixture of digested supernatant sewage sludge and cow dung slurry in different proportions. The effect of operating variables such as COD of the effluent, bed expansion, minimum fluidization velocity on efficiency of treatment and recovery of biogas was investigated. The treated wastewater was analysed for recycling and reuse to ensure an alternative for sustainable water resourse management. The maximum efficiency of treatment was found to be 82% and the nitrogen enriched digested sludge was recommended for agricultural use.

Treatment of anti-osmotic drug based pharmaceutical effluent in an upflow anaerobic fluidized bed system.

During the production of Cephradine (a main constituent of anti-osmotic drug) a large quantity of concentrated effluent was produced. The main polluting compounds in this effluent are osmotic drug, acetic acid and ammonia. The feasibility of using a fluidized bed reactor under anaerobic condition with bioaugmentation to treat anti-osmotic drug based pharmaceutical effluent was evaluated. The main objective of the study was to show that bioaugmentation could be used to promote biological treatment to applications where conventional operation might be difficult or unfavourable. The effluent with chemical oxygen demand (COD) of 14000-18000 mg/l was treated in a fluidized bed reactor with a hydraulic retention time of 3-12 h. The reactor was unable to maintain consistent removal in conventional mode of operation due to an inability to retain and grow biomass. The COD reduction (%) after inoculation from a sequencing batch reactor was related to influent concentration, mass of inoculum and hydraulic retention time characterized by calculating the initial food to microorganism ratio. The role of volatile fatty acid (VFA) as cosubstrate was assessed with respect to COD reduction (%). Continuous COD reduction (%) attained a maximum value of 88.5% using bioaugmentation through periodic addition of acclimated cells every 2 days with 30-73.2 g of cells from an off-line enricher reactor.

Bioaugmentation and anaerobic treatment of pharmaceutical effluent in fluidized bed reactor.

The start-up of an anaerobic fluidized bed reactor was carried out using a single inoculum (supernatant of anaerobic digester) and later on with multiple inoculum (a mixture of supernatant of anaerobic digester and volatile fatty acid (VFA)) to achieve a faster start-up. Then regular experiments were carried out to study the effect of hydraulic retention time (HRT) on COD removal (%) and biogas production. The pharmaceutical effluent with COD of 2000 to 4000 mg/L was treated in a fluidized bed reactor using an enricher-reactor concept with a hydraulic retention times of 3 (Uf = 6 Umf) to 24 (Uf = 1.5 Umf) hr. The maximum COD removal (%) of 91.2 and a maximum biogas production of 5.62 L/d were obtained at 24 hr HRT for a maximum COD concentration of 4000 mg/L corresponding to a fluidization velocity (Uf) of 20 m/hr (1.5 Umf) using a granular activated carbon bed of average size 700 microns.

Bioaugmentation and treatment of cephalexin drug-based pharmaceutical effluent in an upflow anaerobic fluidized bed system.

Cephalexin is a constituent of the cephalosporin group used for the treatment of bronchitis and other heart diseases due to its enhanced oral activity. The effluent from these industries contains a disintegrated form of the drug contributing high chemical oxygen demand (COD), volatile solids and organic solvent. A laboratory-scale study was conducted to evaluate the efficiency of a fluidized bed reactor operated under anaerobic condition with bioaugmentation to treat the cephalexin containing pharmaceutical factory effluent. The main objective of the study was to show that bioaugmentation could be used to promote biological treatment to applications where conventional operation might be difficult or unfavourable. The effluent, with COD of 12,000-15,000 mg/l, was diluted and studied in single and multiple inoculation experiments with hydraulic retention times of 3-12 h. The removal efficiency after inoculation from an anaerobic sequencing batch reactor was related to influent concentration, mass of inoculum and hydraulic retention time characterized by calculating the initial food to microorganism ratio. Continuous COD removal efficiency attained a maximum value of 88.5% using bioaugmentation through periodic addition of acclimated cells every 2 days with 30-73.2 g of cells from an off-line enricher-reactor.

Apolipoprotein B variant derived from rat intestine.

A variant of apolipoprotein B has been observed in the lymph lipoproteins [chylomicrons, very low density lipoproteins (VLDL), and low density lipoproteins (LDL)] of rats, in the plasma VLDL of fed rats, and in the plasma VLDL and LDL of rats fed a high-fat, high-cholesterol diet. It is the sole apolipoprotein B in the chylomicrons and VLDL of lymph. It differs from the apolipoprotein B of normal plasma LDL in its immunological properties and in its apparent molecular weight from electrophoresis on 3.5% NaDodSO4/polyacrylamide gel.

Effect of alpha-p-chlorophenoxyisobutyrate on the metabolism of isoprenoid compounds in the rat.

1. Feeding of alpha-p-chlorophenoxyisobutyrate (CPIB) to rats increased ubiquinone concentration in the liver but not in other tissues. The increase was progressive with the time of feeding and related to the concentration of CPIB in the diet. 2. Incorporation of [1-(14)C]acetate, but not of [2-(14)C]mevalonate, into sterols in the liver in vivo or by liver slices in vitro was decreased on feeding the rats with CPIB. However, incorporation of mevalonate into ubiquinone increased. 3. CPIB, when added in low concentrations to liver slices, had no effect on isoprene synthesis from acetate; higher concentrations, however, were inhibitory. 4. No activation of ubiquinone synthesis from mevalonate was observed when CPIB was added to the liver slices synthesizing ubiquinone. 5. The increase in ubiquinone in CPIB-fed animals appears to be due to increased synthesis in the initial stages and to decreased catabolism in the later stages. 6. An inverse relationship was found between the concentration of ubiquinone in the liver and the serum sterol concentration in CPIB-fed rats.